4.89
price down icon2.78%   -0.14
after-market Dopo l'orario di chiusura: 4.98 0.09 +1.84%
loading
Precedente Chiudi:
$5.03
Aprire:
$4.99
Volume 24 ore:
289.63K
Relative Volume:
0.71
Capitalizzazione di mercato:
$47.87M
Reddito:
$21.73M
Utile/perdita netta:
$-91.17M
Rapporto P/E:
-6.6081
EPS:
-0.74
Flusso di cassa netto:
$-286.43M
1 W Prestazione:
+29.02%
1M Prestazione:
+26.03%
6M Prestazione:
-52.80%
1 anno Prestazione:
-79.28%
Intervallo 1D:
Value
$4.80
$5.1599
Intervallo di 1 settimana:
Value
$3.71
$5.42
Portata 52W:
Value
$3.56
$28.60

Bluebird Bio Inc Stock (BLUE) Company Profile

Name
Nome
Bluebird Bio Inc
Name
Telefono
339-499-9300
Name
Indirizzo
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Name
Dipendente
0
Name
Cinguettio
@bluebirdbio
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
BLUE's Discussions on Twitter

Confronta BLUE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BLUE
Bluebird Bio Inc
4.89 47.87M 21.73M -91.17M -286.43M -0.74
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-24 Aggiornamento JP Morgan Underweight → Neutral
2024-11-15 Downgrade BofA Securities Buy → Neutral
2024-11-15 Downgrade JP Morgan Neutral → Underweight
2024-08-15 Downgrade JP Morgan Overweight → Neutral
2023-12-11 Downgrade HSBC Securities Hold → Reduce
2023-12-08 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2023-10-17 Iniziato Cantor Fitzgerald Neutral
2023-09-06 Iniziato HSBC Securities Buy
2023-07-19 Aggiornamento BofA Securities Neutral → Buy
2023-06-01 Aggiornamento Barclays Equal Weight → Overweight
2023-04-28 Iniziato JP Morgan Overweight
2023-03-07 Iniziato Robert W. Baird Outperform
2022-08-05 Aggiornamento Barclays Underweight → Equal Weight
2022-08-02 Aggiornamento Raymond James Mkt Perform → Outperform
2022-04-06 Downgrade Cowen Outperform → Market Perform
2022-03-07 Downgrade Barclays Equal Weight → Underweight
2021-11-08 Reiterato Barclays Equal Weight
2021-11-08 Reiterato Canaccord Genuity Hold
2021-11-08 Downgrade Goldman Neutral → Sell
2021-11-08 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-11-08 Reiterato RBC Capital Mkts Sector Perform
2021-11-08 Reiterato Wedbush Neutral
2021-11-08 Reiterato Wells Fargo Equal Weight
2021-08-10 Downgrade Canaccord Genuity Buy → Hold
2021-08-10 Downgrade Goldman Buy → Neutral
2021-08-10 Downgrade Wells Fargo Overweight → Equal Weight
2021-08-10 Ripresa William Blair Mkt Perform
2021-08-09 Downgrade SVB Leerink Outperform → Mkt Perform
2021-07-01 Downgrade Berenberg Buy → Hold
2021-03-10 Aggiornamento Mizuho Neutral → Buy
2021-02-17 Downgrade JP Morgan Overweight → Neutral
2021-02-16 Downgrade BofA Securities Buy → Neutral
2021-02-16 Downgrade Wedbush Outperform → Neutral
2021-02-16 Downgrade William Blair Outperform → Mkt Perform
2020-12-09 Downgrade Maxim Group Buy → Hold
2020-11-11 Iniziato Berenberg Buy
2020-11-05 Downgrade BMO Capital Markets Outperform → Market Perform
2020-11-05 Downgrade Barclays Overweight → Equal Weight
2020-11-05 Downgrade Stifel Buy → Hold
2020-11-02 Aggiornamento William Blair Mkt Perform → Outperform
2020-10-20 Iniziato Mizuho Buy
2020-05-13 Iniziato RBC Capital Mkts Outperform
2020-03-27 Aggiornamento Stifel Hold → Buy
2020-02-19 Downgrade Raymond James Outperform → Mkt Perform
2020-02-03 Ripresa BofA/Merrill Buy
2020-02-03 Aggiornamento Evercore ISI In-line → Outperform
2019-12-13 Aggiornamento Oppenheimer Perform → Outperform
2019-11-26 Aggiornamento SVB Leerink Mkt Perform → Outperform
2019-11-19 Downgrade Evercore ISI Outperform → In-line
2019-11-04 Aggiornamento Wedbush Neutral → Outperform
2019-10-01 Iniziato Stifel Hold
2019-08-12 Downgrade William Blair Outperform → Mkt Perform
2019-06-18 Aggiornamento Maxim Group Hold → Buy
Mostra tutto

Bluebird Bio Inc Borsa (BLUE) Ultime notizie

pulisher
Apr 02, 2025

Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Xcellbio Announces Commercial Licensing & Supply Agreement to Support Commercial Production of Gene Therapy for Sickle Cell disease - Business Wire

Apr 02, 2025
pulisher
Mar 31, 2025

BlueBird Shares Are Up Today: What's Going On? - Benzinga

Mar 31, 2025
pulisher
Mar 31, 2025

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Mar 31, 2025
pulisher
Mar 31, 2025

Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumpsbluebird bio (NASDAQ:BLUE) - Benzinga

Mar 31, 2025
pulisher
Mar 31, 2025

Bluebird Bio Receives $4.50 Per Share Acquisition Proposal From Ayrmid - Nasdaq

Mar 31, 2025
pulisher
Mar 31, 2025

bluebird bio’s SWOT analysis: biotech firm’s stock faces cash crunch, product potential - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Bluebird bio rises on non-binding bid for up to $110.5 million - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Bluebird bio receives non-binding bid for up to $110.5 million - MSN

Mar 31, 2025
pulisher
Mar 29, 2025

Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 29, 2025
pulisher
Mar 29, 2025

Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more - MSN

Mar 29, 2025
pulisher
Mar 29, 2025

Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more (T:NYSE) - Seeking Alpha

Mar 29, 2025
pulisher
Mar 29, 2025

bluebird bio confirms rival takeover bid - The Pharma Letter

Mar 29, 2025
pulisher
Mar 29, 2025

Bluebird Bio Stock Leaps On Ayrmid Offer Amid Financial Strain - Finimize

Mar 29, 2025
pulisher
Mar 29, 2025

Bluebird Bio Draws New Bid, Sending Shares Climbing - Finimize

Mar 29, 2025
pulisher
Mar 28, 2025

Ayrmid Proposes to Acquire Bluebird Bio, Inc. (BLUE) with Premiu - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

New suitor emerges for struggling bluebird bio - FirstWord Pharma

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird Bio (BLUE) Receives Acquisition Offer from Ayrmid - GuruFocus.com

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer - Fierce Pharma

Mar 28, 2025
pulisher
Mar 28, 2025

bluebird bio (BLUE) Receives Higher Bid from Ayrmid Pharma - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

bluebird bio sees higher offer for company from Ayrmid Pharma - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird Bio (BLUE) Receives Higher Buyout Bid from Ayrmid - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird gets rival takeout offer from Ayrmid - BioPharma Dive

Mar 28, 2025
pulisher
Mar 28, 2025

bluebird bio receives higher acquisition offer from Ayrmid - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird Bio shares rally 11% in late trade on buyout offer - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

bluebird bio receives higher acquisition offer from Ayrmid By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird bio reports another acquisition offer for $45M upfront - The Business Journals

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird Bio Gets Rival Buyout Proposal From Ayrmid; Shares Jump After Hours - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird bio stock rises on new acquisition proposal By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird bio stock rises on new acquisition proposal - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird Bio confirms receipt non-binding proposal from Ayrmid - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird Bio Confirms Receipt Of An Unsolicited Non-Binding Proposal From Ayrmid - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid - Business Wire

Mar 28, 2025
pulisher
Mar 28, 2025

Sickle Cell Treatment Market Business Outlook and Growth - openPR

Mar 28, 2025
pulisher
Mar 28, 2025

bluebird bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 28, 2025
pulisher
Mar 26, 2025

T-Cell Immunotherapy Market is Booming Worldwide |Medigene,Bluebird Bio,Novartis - openPR

Mar 26, 2025
pulisher
Mar 24, 2025

Sickle Cell Disease Treatment Market: New Drug Approvals - openPR

Mar 24, 2025
pulisher
Mar 21, 2025

Breaking Notice: Rosen, a Globally Recognized Law Firm, Encourages bluebird bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – BLUE - Business Wire

Mar 21, 2025
pulisher
Mar 21, 2025

Gene therapy loses luster as investors eye quicker returns from weight-loss drugs - Reuters

Mar 21, 2025
pulisher
Mar 21, 2025

Drug developers show mixed performance in early 2025 - BioWorld Online

Mar 21, 2025
pulisher
Mar 21, 2025

Sickle Cell Disease Pipeline 2025 Detailed Clinical Trials - openPR

Mar 21, 2025
pulisher
Mar 18, 2025

Carlyle's bluebird Deep Discount Buyout (Rating Upgrade) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc.BLUE - PR Newswire

Mar 17, 2025
pulisher
Mar 14, 2025

Gene therapy efforts active, despite low Bluebird, 2seventy bids - BioWorld Online

Mar 14, 2025
pulisher
Mar 13, 2025

BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc.BLUE - Business Wire

Mar 13, 2025
pulisher
Mar 13, 2025

Gene Therapy Market Future Business Opportunities 2025-2032 | - openPR

Mar 13, 2025
pulisher
Mar 12, 2025

Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M Deal - Dealbreaker

Mar 12, 2025
pulisher
Mar 12, 2025

Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs - BioSpace

Mar 12, 2025
pulisher
Mar 12, 2025

bluebird bio (NASDAQ:BLUE) Coverage Initiated at StockNews.com - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Stem Cell Therapy Market Growth | Trends, Size & Forecast - openPR

Mar 12, 2025

Bluebird Bio Inc Azioni (BLUE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Capitalizzazione:     |  Volume (24 ore):